¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"primary hepatic carcinoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • verrucous carcinoma
    »ç¸¶±Í¸ð¾ç¾ÏÁ¾
  • delayed primary suture
    Áö¿¬ÀÏÂ÷ºÀÇÕ
  • primary
    ÀÏÂ÷-, ¿ø¹ß-
  • primary action
    ÀÏÂ÷ÀÛ¿ë
  • primary affect hunger
    ÀÏÂ÷Á¤µ¿°¥¸Á, ÀÏÂ÷¾ÖÁ¤°¥¸Á
  • primary aldosteronism
    ¿ø¹ß¾Ëµµ½ºÅ×·ÐÁõ
  • primary amebic meningoencephalitis
    ¿ø¹ß¾Æ¸Þ¹Ù¼ö¸·³ú¿°
  • primary amenorrhea
    ¿ø¹ß¹«¿ù°æ
  • primary amnion
    ÀÏÂ÷¾ç¸·, ¿ø½Ã¾ç¸·
  • primary amyloidosis
    ¿ø¹ß¾Æ¹Ð·ÎÀ̵åÁõ
  • primary aqueous
    ÀÏÂ÷¹æ¼ö, ¿ø¹æ¼ö
  • primary atelectasis
    ¿ø¹ß¹«±âÆó
  • primary atypical pneumonia
    ¿ø¹ßºñÁ¤ÇüÆó·Å
  • primary biliary cirrhosis
    ¿ø¹ß¾µ°³°ü°£°æÈ­(Áõ)
  • primary brain vesicles
    ÀÏÂ÷³úÆ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • primary olfactory receiving area
    ÀÏÂ÷Èİ¢¿µ¿ª
  • primary sensory area
    ÀÏÂ÷°¨°¢±¸¿ª
  • primary bronchus
    ÀÏÂ÷±â°üÁö
  • primary membrane bone
    ¼¼¸Á¼¶À¯¸·»À, ÀÏÂ÷¸·»À
  • primary cancer
    ¿ø¹ß¾Ï
  • primary cardiomyopathy
    ¿ø¹ß½ÉÀå±ÙÀ°º´Áõ
  • primary cement
    ÀÏÂ÷½Ã¸àÆ®Áú
  • primary character
    ÀÏÂ÷¼º°Ý
  • primary coil
    ÀÏÂ÷ÄÚÀÏ
  • primary complex
    Ãʱ⺯ȭ±º, ¿ø¹ßº¹ÇÕü
  • primary constriction
    (¢¡centromere) ¸Åµì, µ¿¿øÃ¼, Áß½ÉÀý
  • primary contact
    ÀÏÂ÷Á¢ÃË
  • primary culture
    óÀ½½É±â
  • primary biliary cirrhosis
    ¿ø¹ß¾µ°³°ü°£°æÈ­(Áõ)
  • primary health care
    ÀÏÂ÷º¸°ÇÀÇ·á
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • hepatic first pass effect
    °£ÃÊȸÅë°úÈ¿°ú.
  • hepatic fistula
    °£·ç(°£·ç).
  • hepatic flexure <³ª> f. coli dextra
    ¿ì°áÀå°î(éÓÌ¿ ÍØ) °£¸¸°î(ÊÜØ¶ÍØ) .
  • hepatic flexure <³ª> f. coli dextra
    ¿ì°áÀå°î(¿ì°áÀå°î), °£¸¸°î(°£¸¸°î) .
  • hepatic flexure ³ª f. coli dextra
    ¿ì°áÀå°î(éÓÌ¿ ÍØ) °£¸¸°î(ÊÜØ¶ÍØ) .
  • hepatic glycogen
    °£(ÊÜ)±Û¸®ÄÚ°Õ.
  • hepatic gutter
    °£±¸(ÊÜϵ).
  • hepatic hilum
    °£¹®
  • hepatic infantilism
    °£¼º¼Ò¾ÆÁõ.
  • hepatic insufficiency
    °£(±â´É)ºÎÀü.
  • hepatic lipase
    °£¸®ÆÄÁ¦
  • hepatic lobes
    °£¿±
  • hepatic lobule
    ¸®°£¼Ò¿±(ÊÜá³ç¨).
  • hepatic lobule
    °£¼Ò¿±
  • hepatic lobules
    °£¼Ò¿±
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • hepatic part of inferior vena cava
    ¾Æ·¡´ëÁ¤¸Æ°£ºÎºÐ
  • hepatic plate
    °£¼¼Æ÷ÆÇ
  • hepatic plexus
    °£½Å°æ¾ó±â
  • hepatic plexus <³ª> p. hepaticius
    °£½Å°æ¾ó±â, °£½Å°æÃÑ.
  • hepatic plexus <³ª> p. hepaticus
    °£½Å°æÃÑ.
  • hepatic porphyria
    °£¼ºÆ÷¸£ÇǸ®¾Æ.
  • hepatic portal <³ª> porta hepatica
    °£¹® (ÊÜÚ¦).
  • hepatic portal <³ª> porta hepatis
    °£¹® (°£¹®).
  • hepatic portal vein
    °£¹®¸Æ(°£¹®¸Æ).
  • hepatic portal vein
    °£¹®¸Æ(ÊÜÚ¦Øæ).
  • hepatic portal vein
    °£¹®¸Æ
  • hepatic prolylhydroxylase
    °£ÇÁ·Ñ¸±È÷µå·Ï½Ç¶óÁ¦
  • hepatic prominence
    °£À¶±â
  • hepatic pulsation
    °£(Àå)¹Úµ¿.
  • hepatic pulse
    °£¸Æ(ÊÜØæ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
COACH cerebellar vermis hypoplasia/aplasia-oligophrenia-congenital ataxia-ocular colobomata-hepatic fibros...
DIHE drug-induced hepatic encephalopathy
EHBF estimated hepatic blood flow; exercise hyperemia blood flow; extrahepatic blood flow
FHF fetal heart frequency; fulminant hepatic failure
FHVP free hepatic vein pressure
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
HC Hepatic cirrhosis
HGO Hepatic glucose output
HGP Hepatic glucose production
HNF4 Hepatic nuclear factor 4
HPVG Hepatic portal venous gas
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • non-nociceptive myelinated primary afferent
    ºñÄ§ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯, ºñÀ¯ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯
  • primary
    ÀÏÂ÷¼º, ¿ø¹ß¼º, ¿ø¹ß¼ºÀÇ, ÀÏÂ÷, ÀÏÂ÷ÀÇ, ÀÏÂ÷¼ºÀÇ, Á¦ÀÏÀÇ, ÃʱâÀÇ, ¿ø¹ßÀÇ, ÁÖµÈ
    ¹ß»ýµÇ´Â ½Ã±âÀÇ ¼ø¼­¿¡ À־ óÀ½ÀÎ.
  • primary adaptation
    ÀÏÂ÷ ¼øÀÀ, ÀÏÂ÷¼º ¼øÀÀ
  • primary adrenocortical insuffciency
    ¿ø¹ß¼º ºÎ½Å ÇÇÁú ±â´É ºÎÀü
  • primary afferent axon
    ÀÏÂ÷ ±¸½É¼º Ãà»è
  • primary afferent cell body
    ÀÏÂ÷ ±¸½É¼º ¼¼Æ÷ü
  • primary afferent fiber
    ÀÏÂ÷ ±¸½É ¼¶À¯
  • primary afferent nociceptive transmitter
    ÀÏÂ÷ ±¸½É À¯ÇØ ¼ö¿ë¼º Àü´Þ ¹°Áú
  • primary afferent nociceptor input
    ÀÏÂ÷ ±¸½É¼º Ä§ÇØ¼ö¿ëü ÀÔ·Â, ÀÏÂ÷ ±¸½É¼º À¯Çؼö¿ë±â ÀÔ·Â
  • primary afferent projection
    ÀÏÂ÷ ±¸½É¼º Åõ»ç
  • primary afferent terminal
    ÀÏÂ÷ ±¸½É¼º ¸»´Ü
  • primary amenorrhea
    ¿ø¹ß ¹«¿ù°æ, ¿ø¹ß¼º ¹«¿ù°æ
  • primary amyloidosis
    ¿ø¹ß¼º À¯ÀüºÐÁõ, ¿ø¹ß ¾Æ¹Ð·ÎÀ̵åÁõ, ¿ø¹ß¼º ¾Æ¹Ð·ÎÀ̵åÁõ
  • primary anesthesia
    ÀÏÂ÷ ¸¶Ãë
  • primary benign leukoplakias
    ¿ø¹ß¼º ¾ç¼º ¹é¹ÝÁõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
carcinoma, endometrioid Ovarian carcinoma which resembles typical carcinoma of the endometrium and may be seen with a synchronous endometrial carcinoma. When they appear together, both tend to be of low stage.
(12 Dec 1998)
carcinoma ex pleomorphic adenoma <tumour> Carcinoma arising in a benign mixed tumour of a salivary gland, characterised by rapid enlargement and pain.
(05 Mar 2000)
carcinoma, giant cell An epithelial neoplasm characterised by unusually large anaplastic cells. It is highly malignant with fulminant clinical course, bizarre histologic appearance and poor prognosis. It is most common in the lung and thyroid.
(12 Dec 1998)
carcinoma, hepatocellular Primary carcinoma of the liver cells. It ranges from a well-differentiated tumour difficult to distinguish from normal hepatocytes to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic or may form giant cells. Several classification schemes have been suggested. Hepatocellular carcinoma is very rare in the united states and western europe, but it is one of the most common cancers in eastern asia and sub-saharan africa. The cases are preponderantly male and, racially, whites have the lowest rates.
(12 Dec 1998)
carcinoma, infiltrating duct An invasive (infiltrating) carcinoma of the breast. This carcinoma in which no special histological feature is recognised is designated nos or not otherwise specified and is by far the most common ductal tumour, accounting for almost 70% of breast cancers. It is characterised by stony hardness upon palpation. It commonly metastasizes to the axillary lymph nodes and its prognosis is the poorest of the various ductal types.
(12 Dec 1998)
carcinoma in situ Cancer that involves only the cells in which it began and has not spread to other tissues. Lobular carcinoma in situ is found in the lobules of the breast. Ductal carcinoma in situ (also called intraductal carcinoma) arises in the ducts.
(16 Dec 1997)
carcinoma, intraductal, noninfiltrating A noninvasive (noninfiltrating) carcinoma of the breast characterised by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma. Its true incidence is uncertain but all noninvasive breast carcinomas comprise almost 5% of all neoplastic lesions of the female breast, with this carcinoma accounting for about 50% of these, or 2.5%-2.8% of all tumours.
(12 Dec 1998)
carcinoma, islet cell A carcinoma of the islets of langerhans.
(12 Dec 1998)
carcinoma, large cell A tumour of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic.
(12 Dec 1998)
carcinoma, lewis lung A carcinoma discovered by dr. Margaret r. Lewis of the wistar institute in 1951. This tumour originated spontaneously as a carcinoma of the lung of a c57bl mouse. The tumour does not appear to be grossly haemorrhagic and the majority of the tumour tissue is a semifirm homogeneous mass. It is also called 3ll and llc and is used as a transplantable malignancy.
(12 Dec 1998)
carcinoma, lobular A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumours in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces.
(12 Dec 1998)
carcinoma, medullary A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies.
(12 Dec 1998)
carcinoma, merkel cell A carcinoma arising from merkel cells located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of merkel cell carcinoma, occurring generally in elderly patients.
(12 Dec 1998)
carcinoma, mucoepidermoid A tumour of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumours of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumour of the parotid.
(12 Dec 1998)
carcinoma myxomatodes An obsolete term for a form of colloid cancer in which there is myxomatous metaplasia of the cellular fibrous stroma.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á